Compliance Issues with Alternative Funding Programs for Specialty Drugs

Our analysis indicates that Alternative Funding Programs which exclude specialty drugs from coverage and then use Patient Assistance Programs for funding are exposing employers and employees to ERISA and IRS risks and violations. More importantly it is likely a violation of fiduciary responsibility for self-funded plans. See the details of the analysis below.